John E. Pippen, M.D. specializes in medical oncology, specifically, in the care of patients with breast cancer. He is board certified in internal medicine and medical oncology by the American Board of Internal Medicine. He is interested in clinical research trials involving the prevention and treatment of breast cancer. Dr. Pippen now takes care of a large number of patients with breast cancer as well as other solid tumors, and is actively involved in clinical trials with The US Oncology Network.
Dr. Pippen received an M.D. in 1982 from the University of Texas Southwestern Medical School in Dallas. At Baylor University Medical Center, Dallas, Texas, Dr. Pippen completed an internal medicine internship and residency from 1982 to 1985, and a medical oncology fellowship from 1993 to 1995. He received a B.S. in Zoology in 1977 from Texas A&M University, College Station.
Accolades & Memberships:
Internal medicine practice, Baylor University Medical Center, 1985-1993; attending physician, Baylor Medical Center, 1985-2003. Fellow, American College of Physicians; Member of Career Development Committee, American Society of Clinical Oncology; principal investigator for Faslodex clinical trial that led to FDA approval; faculty member at the 2003 American Society Clinical Oncology meeting, Chicago, IL. In addition to being an active member of multiple societies, Dr. Pippen is currently Past-Chair of the Career Development Subcommittee of the American Society of Clinical Oncology, and Chair-Elect of the Maintenance of Certification Subcommittee. Dr. Pippen has previously served on the Cancer Education Committee of ASCO.
Attending Physician and Chair of the Breast Tumor Site Committee, Baylor Sammons Cancer Center, Dallas Texas
Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: a report of a tamoxifen exemestane adjuvant multicenter trial substudy.
Journal of Clinical Oncology, 2007
Determination of oestrogen-receptor status and erb b2 status of breast carcinoma: a gene expression profiling study.
The Lancet, 2007
Maintenance of certification: my perspective.
Journal of Oncology Practice, 2007
Phase II study of weekly albumin bound paclitaxel for patients with breast cancer heavily pretreated with taxanes.
Clinical Breast Cancer
Time to response: comparison of fulvestrant and oral endocrine agents.
Clinical Breast Cancer, 2006